MedTrace Logo

Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines

NCT00984295 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1913

Last updated 2015-08-07

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and immunogenicity of ProQuad when administered concomitantly and nonconcomitantly with Tripedia and Comvax.

Conditions

Interventions

BIOLOGICAL

Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live

A single 0.5 mL subcutaneous injection at Day 0

BIOLOGICAL

Comparator: Tripedia

A single 0.5 mL intramuscular injection (at Day 0 or Day 42)

BIOLOGICAL

Comparator: Comvax

A single 0.5 mL intramuscular injection (at Day 0 or Day 42)

BIOLOGICAL

Comparator: Varivax

A single 0.5 mL subcutaneous injection at Day 0

BIOLOGICAL

Comparator: M-M-R II

A single 0.5 mL subcutaneous injection at Day 0

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
15 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2000-06-30
Primary Completion
2001-10-31
Completion
2001-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00984295 on ClinicalTrials.gov